My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format

Send to:

Choose Destination

    N Engl J Med. 2006 Oct 5;355(14):1409-12.

    The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.

    Steinbrook R.

    rsteinbrook@attglobal.net

    Comment on:

    PMID: 17021315 [PubMed - indexed for MEDLINE]

    Publication Types, MeSH Terms, Substances

    Publication Types:

    MeSH Terms:

    Substances:

    LinkOut - more resources

    Full Text Sources:

    Medical:

    Supplemental Content

    Click here to read

    Related articles

    Cited by 12 PubMed Central articles

    Patient drug information

    • Bevacizumab Injection (Avastin®)

      Bevacizumab is used with chemotherapy to treat cancer of the colon (large intestine) or rectum that has spread to other parts of the body. Bevacizumab is also used with chemotherapy to treat certain types of lung cancer....

    • Ranibizumab Injection (Lucentis®)

      Ranibizumab is used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other ...

    • Source: AHFS Consumer Medication Information

    All links from this record

    • Related Articles

      Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.

    • Substance (MeSH Keyword)

      PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

    • Cited in PMC

      Full-text articles in the PubMed Central Database that cite the current articles.

    Recent activity